Characteristics of the Pro225his mutation in Human Immunodeficiency Virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1

Journal of Virology

Volumn 71, Issue 11, 1997, Pages 8195-8203

  Pelemans, Heidi ^a   Esnouf, Robert ^a   Dunkler, Anke ^b   Parniak, Michael A ^c   Vandamme, Anne Mieke ^a   Karlsson, Anna ^d   De Clercq, Erik ^a   Kleim, Jörg Peter ^b   Balzarini, Jan ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b SANOFI   (France)

^c MCGILL UNIVERSITY   (Canada)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXYGUANOSINE; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 6 CHLORO 3,3 DIMETHYL 4 (ISOPROPENYLOXYCARBONYL) 3,4 DIHYDROQUINOXALIN 2(1H) THIONE; 9 CHLORO 4,5,6,7 TETRAHYDRO 5 METHYL 6 (3 METHYL 2 BUTENYL)IMIDAZO[4,5,1 JK][1,4]BENZODIAZEPINE 2(1H) THIONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; EMIVIRINE; LAMIVUDINE; LOVIRIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANOCARBOTHIAMIDE; NEVIRAPINE; QUINOXALINE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; S 2720; TALVIRALINE; TIVIRAPINE; UC 10; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS MUTATION;

EID: 0030879805     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.11.8195-8203.1997     Document Type: Article

References (26)

1. Balzarini, J., M.-J. Pérez-Pérez, A. San-Félix, M.-J. Camarasa, I. C. Bathurst, P. J. Barr, and E. De Clercq. 1992. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″, 2″-dioxide] thymidine (TSAO-T). J. Biol. Chem. 267:11831-11838.
2. Balzarini, J., A. Karlsson, C. Meichsner, A. Paessens, G. Riess, E. De Clercq, and J.-P. Kleim. 1994. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J. Virol. 68:7986-7992.
3. Camarasa, M.-J., M.-J. Pérez-Pérez, A. San-Félix, J. Balzarini, and E. De Clercq. 1992. 3′-spiro nucleosides, a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo- and -ribofuranose]-3′-spiro-5″-[4″-amino-1″,2″- oxathiole 2″,2″-dioxide] (TSAO) pyrimidine nucleosides. J. Med. Chem. 35:2721-2727.
4. D'Aquila, R. T., and W. C. Summers. 1989. HIV-1 reverse transcriptase/ ribonuclease H: high level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction. J. Acquired Immune Defic. Syndr. 2:579-587.
5. De Clercq, E. 1994. HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47:155-169.
6. De Clercq, E. 1996. What can be expected from non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the treatment of human immunodeficiency virus type 1 (HIV-1) infections? Rev. Med. Virol. 6:97-117.
7. Dueweke, T. J., T. Pushkarskaya, S. M. Poppe, S. M. Swaney, J. Q. Zhao, I. S. Y. Chen, M. Stevenson, and W. G. Tarpley. 1993. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proc. Natl. Acad. Sci. USA 90:4713-4717.
8. Esnouf, R., J. Ren, C. Ross, Y. Jones, D. Stammers, and D. Stuart. 1995. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 2:303-308.
9. Esnouf, R. M., J. Ren, A. L. Hopkins, C. K. Ross, E. Y. Jones, D. K. Stammers, and D. I. Stuart. 1997. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine U-90152 explain resistance mutations for this non-nucleoside inhibitor. Proc. Natl. Acad. Sci. USA 94:3984-3989.
10. Esnouf, R. M. 1997. An extensively modified version of MolScript which includes greatly enhanced colouring capabilities. J. Mol. Graphics 15:133-138.
11. Fletcher, R. S., G. Holleschak, E. Nagy, D. Arion, G. Borkow, Z. Gu, M. A. Wainberg, and M. A. Parniak. 1996. Single-step purification of recombinant wild-type and mutant HIV-1 reverse transcriptase. Protein Expr. Purif. 7: 27-32.
12. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1992. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxycytidine. J. Virol. 66: 7128-7135.
13. Hopkins, A. L., J. Ren, R. M. Esnouf, B. E. Willcox, E. Y. Jones, C. Ross, T. Miyasaka, K. T. Walker, H. Tanaka, D. K. Stammers, and D. I. Stuart. 1996. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J. Med. Chem. 39:1589-1600.
14. Kleim, J.-P., R. Bender, U. M. Billhardt, C. Meichsner, G. Riess, M. Rösner, I. Winkler, and A. Paessens. 1993. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob. Agents Chemother. 37:1659-1664.
15. Kleim, J.-P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, and G. Riess. 1994. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology 200:696-701.
16. Kleim, J.-P., R. Bender, R. Kirsch, C. Meichsner, A. Paessens, M. Rösner, H. Rübsamen-Waigmann, R. Kaiser, M. Wichers, K. E. Schneweis, I. Winkler, and G. Riess. 1995. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrob. Agents Chemother. 39:2253-2257.
17. Kleim, J.-P., M. Rösner, I. Winkler, A. Paessens, R. Kirsch, Y. Hsiou, E. Arnold, and G. Riess. 1996. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74→Val or Ile and Val-75→Leu or Ile) HIV-1 mutants. Proc. Natl. Acad. Sci. USA 93:34-38.
18. Kleim, J.-P., I. Winkler, M. Rösner, R. Kirsch, H. Rübsamen-Waigmann, A. Paessens, and G. Riess. 1997. In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097. Virology 231:112-118.
19. Kleim, J.-P., et al. Unpublished data.
20. Kraulis, P. J. 1991. MolScript: a program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24:946-950.
21. Nijhuis, M., R. Schuurman, D. de Jong, P. Schipper, S. Danner, and C. Boucher. 1997. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication, abstr. 92.
22. Pérez-Pérez, M.-J., A. San-Félix, J. Balzarini, E. De Clercq, and M.-J. Camarasa. 1992. TSAO analogues. Stereospecific synthesis and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl]- 3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″, 2″-dioxide] pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 35:2988-2995.
23. Pérez-Pérez, M.-J., A. San-Félix, M.-J. Camarasa, J. Balzarini, and E. De Clercq. 1992. Synthesis of {1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-D-xylo- and β-D-ribofuranosyl]thymine}-3′-spiro-5″-[4″-amino- 1″,2″-oxathiole-2″,2″-dioxide] (TSAO): a novel type of specific anti-HIV agents. Tetrahedron Lett. 33:3029-3032.
24. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
25. Schmit, J.-C., J. Cogniaux, P. Hermans, C. Van Vaeck, S. Sprecher, B. Van Remoortel, M. Witvrouw, J. Balzarini, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1996. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J. Infect. Dis. 174:962-968.
26. Schmit, J.-C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter, E. De Clercq, and A.-M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.